Skip to main content

Advertisement

Table 1 Clinical data on the patients at the time of biopsies

From: Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents

Patient ID Diagnosis Age (years) Gender Disease duration (months) Cumulative cortisone (mg) Imuunosuppressive treatment at second biopsy Autoantibodies Support for diagnosis MMT-8 (%) s-CK (μcat/L) HAQ (0.0–3.0) FI-2 (%)
B A B A B A B A
1 DM 40 M 3 14450.0 Pred, AZA MDA5, SSA, Ro60 MW, S, LD 87.5 87.5 1.3 1.1 1.13 0.75 21.7 27.4
2 PM 73 F 12 6222.5 Pred, MTX Neg MW, CK, MB 85.0 85.0 10.2 1.5 0.5 0.88 18.3 19.1
3 DM 69 F 2 10017.5 Pred, MTX ANA, TIF1γ MW, CK, S, EMG 81.4 91.3 29.3 1.0 0.63 0 0 11.2
4 DM 63 M 0.5 7330.0 Pred, AZA Neg MW, CK, S, EMG 78.8 90.0 48.2 1.0 0,38 0 86.2 100.0
5 DM 45 F 16 6842.5 Pred, MTX ANA, Mi-2 MW, CK, MB, S, EMG 98.8 87.5 43.0 2.1 1.5 0.88 17.3 25.3
6 PM 71 F 12 8415.0 Pred, AZA Neg MW, CK, MB 75.7 100 9.0 3.9 1.25 1.88 NA 17
  1. A after treatment, ANA antinuclear antibodies, AZA azathioprine, B before treatment, CK creatine kinase (reference interval, male: 3.3 μkat/L, female: 2.5 μkat/L), DM dermatomyositis, EMG positive for electromyography, F female, FI-2 Functional Index-2 (0–100 %; impairment in performing repetitions, respective no impairment), HAQ Health Assessment Questionnaire (0.00–3.00; no impairment, respective impairment), LD lactate dehydrogenase (reference interval 105–333 IU/L), M male, MB positive muscle biopsy, MDA5 melanoma differentiation-associated protein 5, MMT-8 manual muscle testing in 8 muscle groups (0–100 %; muscle strength), MTX methotrexate, MW muscle weakness, NA not available, PM polymyositis, Pred prednisone, S skin rash, s-CK serum creatine kinase, SSA anti-Sjögren’s syndrome-related antigen A (also called anti-Ro), TIF1γ transcription intermediary factor 1-gamma